FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281552051> ?p ?o ?g. }

• W4281552051 endingPage "1095" @default.
• W4281552051 startingPage "1087" @default.
• W4281552051 abstract "PurposeTo assess the association between BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine and the risk of active noninfectious uveitis (NIU).DesignRetrospective, population-based study.ParticipantsTwo million six hundred two thousand five hundred fifty-seven people who received the first vaccine dose between December 20, 2020, and April 30, 2021, and 2 441 719 people who received the second vaccine dose between January 10, 2021, and April 30, 2021.MethodsEvents of active NIU were included if they occurred within 21 days after either vaccine dose. Active NIU was defined as newly active or worsening ocular inflammation requiring initiation or increase in local or systemic corticosteroids. Observed cases were compared with the expected number, based on the experience of the population in 2019.Main Outcome MeasuresAge- and sex-adjusted standardized incidence ratios (SIRs) and attributable risks after BNT126b2 vaccination.ResultsOverall, 100 and 88 events of active NIU were recorded within 21 days after the first and second vaccine doses, respectively. Using the experience of the population in 2019 as a reference, after the first dose, the estimated age- and sex-adjusted SIR was 1.41 (95% confidence interval [CI], 1.15–1.71) along with a 21-day attributable risk of 1.12 cases per 100 000 vaccinees. After the second dose, the SIR was 1.31 (95% CI, 1.05–1.62), with an estimated attributable risk of 0.86 cases per 100 000 vaccinees. Anterior uveitis was the most common site of inflammation, occurring in 90.96% of eyes, and idiopathic uveitis was the most common cause (56.38%).ConclusionsThis study suggests that the BNT162b2 mRNA COVID-19 vaccine may be associated with an increased risk of active NIU. However, considering the small effect size and study limitations, this study does not provide proof for a cause-and-effect relationship. The small estimated attributable risks suggest that the impact on public health is relatively minor. To assess the association between BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine and the risk of active noninfectious uveitis (NIU). Retrospective, population-based study. Two million six hundred two thousand five hundred fifty-seven people who received the first vaccine dose between December 20, 2020, and April 30, 2021, and 2 441 719 people who received the second vaccine dose between January 10, 2021, and April 30, 2021. Events of active NIU were included if they occurred within 21 days after either vaccine dose. Active NIU was defined as newly active or worsening ocular inflammation requiring initiation or increase in local or systemic corticosteroids. Observed cases were compared with the expected number, based on the experience of the population in 2019. Age- and sex-adjusted standardized incidence ratios (SIRs) and attributable risks after BNT126b2 vaccination. Overall, 100 and 88 events of active NIU were recorded within 21 days after the first and second vaccine doses, respectively. Using the experience of the population in 2019 as a reference, after the first dose, the estimated age- and sex-adjusted SIR was 1.41 (95% confidence interval [CI], 1.15–1.71) along with a 21-day attributable risk of 1.12 cases per 100 000 vaccinees. After the second dose, the SIR was 1.31 (95% CI, 1.05–1.62), with an estimated attributable risk of 0.86 cases per 100 000 vaccinees. Anterior uveitis was the most common site of inflammation, occurring in 90.96% of eyes, and idiopathic uveitis was the most common cause (56.38%). This study suggests that the BNT162b2 mRNA COVID-19 vaccine may be associated with an increased risk of active NIU. However, considering the small effect size and study limitations, this study does not provide proof for a cause-and-effect relationship. The small estimated attributable risks suggest that the impact on public health is relatively minor." @default.
• W4281552051 created "2022-05-27" @default.
• W4281552051 creator A5005524023 @default.
• W4281552051 creator A5009021620 @default.
• W4281552051 creator A5016800738 @default.
• W4281552051 creator A5017290532 @default.
• W4281552051 creator A5028406223 @default.
• W4281552051 creator A5075459515 @default.
• W4281552051 date "2022-10-01" @default.
• W4281552051 modified "2023-10-16" @default.
• W4281552051 title "Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis" @default.
• W4281552051 cites W2049532432 @default.
• W4281552051 cites W2050766359 @default.
• W4281552051 cites W2051918598 @default.
• W4281552051 cites W2139499737 @default.
• W4281552051 cites W2167499598 @default.
• W4281552051 cites W2809911777 @default.
• W4281552051 cites W2904115191 @default.
• W4281552051 cites W2955068995 @default.
• W4281552051 cites W2979946382 @default.
• W4281552051 cites W3013706373 @default.
• W4281552051 cites W3111255098 @default.
• W4281552051 cites W3127448174 @default.
• W4281552051 cites W3155376666 @default.
• W4281552051 cites W3156146160 @default.
• W4281552051 cites W3159148372 @default.
• W4281552051 cites W3164069651 @default.
• W4281552051 cites W3164764934 @default.
• W4281552051 cites W3165002814 @default.
• W4281552051 cites W3165892222 @default.
• W4281552051 cites W3176603469 @default.
• W4281552051 cites W3176748722 @default.
• W4281552051 cites W3180751199 @default.
• W4281552051 cites W3186510379 @default.
• W4281552051 cites W3189923622 @default.
• W4281552051 cites W3190136280 @default.
• W4281552051 cites W3192369908 @default.
• W4281552051 cites W3195586393 @default.
• W4281552051 cites W3197128389 @default.
• W4281552051 cites W3197259048 @default.
• W4281552051 cites W3197700211 @default.
• W4281552051 cites W3200090586 @default.
• W4281552051 cites W3201153473 @default.
• W4281552051 cites W3202007017 @default.
• W4281552051 cites W3205044984 @default.
• W4281552051 cites W3206505648 @default.
• W4281552051 cites W3209033957 @default.
• W4281552051 cites W3210678339 @default.
• W4281552051 cites W3213516711 @default.
• W4281552051 cites W3214368855 @default.
• W4281552051 cites W3216266300 @default.
• W4281552051 cites W4200406851 @default.
• W4281552051 cites W4200585097 @default.
• W4281552051 cites W4200608310 @default.
• W4281552051 cites W4225815835 @default.
• W4281552051 cites W4226178606 @default.
• W4281552051 cites W4226248453 @default.
• W4281552051 cites W4226321964 @default.
• W4281552051 cites W4226343533 @default.
• W4281552051 doi "https://doi.org/10.1016/j.ophtha.2022.05.015" @default.
• W4281552051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35643168" @default.
• W4281552051 hasPublicationYear "2022" @default.
• W4281552051 type Work @default.
• W4281552051 citedByCount "18" @default.
• W4281552051 countsByYear W42815520512022 @default.
• W4281552051 countsByYear W42815520512023 @default.
• W4281552051 crossrefType "journal-article" @default.
• W4281552051 hasAuthorship W4281552051A5005524023 @default.
• W4281552051 hasAuthorship W4281552051A5009021620 @default.
• W4281552051 hasAuthorship W4281552051A5016800738 @default.
• W4281552051 hasAuthorship W4281552051A5017290532 @default.
• W4281552051 hasAuthorship W4281552051A5028406223 @default.
• W4281552051 hasAuthorship W4281552051A5075459515 @default.
• W4281552051 hasBestOaLocation W42815520511 @default.
• W4281552051 hasConcept C120665830 @default.
• W4281552051 hasConcept C121332964 @default.
• W4281552051 hasConcept C126322002 @default.
• W4281552051 hasConcept C187212893 @default.
• W4281552051 hasConcept C203014093 @default.
• W4281552051 hasConcept C22070199 @default.
• W4281552051 hasConcept C2776194053 @default.
• W4281552051 hasConcept C2908647359 @default.
• W4281552051 hasConcept C44249647 @default.
• W4281552051 hasConcept C61511704 @default.
• W4281552051 hasConcept C71924100 @default.
• W4281552051 hasConcept C99454951 @default.
• W4281552051 hasConceptScore W4281552051C120665830 @default.
• W4281552051 hasConceptScore W4281552051C121332964 @default.
• W4281552051 hasConceptScore W4281552051C126322002 @default.
• W4281552051 hasConceptScore W4281552051C187212893 @default.
• W4281552051 hasConceptScore W4281552051C203014093 @default.
• W4281552051 hasConceptScore W4281552051C22070199 @default.
• W4281552051 hasConceptScore W4281552051C2776194053 @default.
• W4281552051 hasConceptScore W4281552051C2908647359 @default.
• W4281552051 hasConceptScore W4281552051C44249647 @default.
• W4281552051 hasConceptScore W4281552051C61511704 @default.
• W4281552051 hasConceptScore W4281552051C71924100 @default.
• W4281552051 hasConceptScore W4281552051C99454951 @default.

• next